PATENT CLAIM ANALYSIS

Application Number: 16308908
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-05
Patent Classification: ["424", "465000"]

Abstract:
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of a non-purine selective inhibitor of xanthine oxidase, in particular Febuxostat and an effective amount of an alkalizing agent. It also relates to a process for the preparation thereof.

Claim (Index 5):
The pharmaceutical composition according to  claim 1 , wherein magnesium oxide is present in the formulation in amount 3-10%.

Metadata:
- Claim Count in Document: 16.0
- Percentile: 98.0
- Lexical Diversity: 1.325
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['13160572', '15010212', '12739475', '14006032', '13990632']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7163203113644621
- 35 USC 102 Novelty (BERT): 0.5040106725283149
- Combined Prediction Score: 0.6950893474808473
- Mean Citation Score: 167.35468000000003
- Max Citation Score: 190.09056
- Similarity Product: 111.85119018756868

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test